“The present condition has exposed some structural weaknesses during the EU’s medicines offer chain plus a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides explained. She encouraged that provide chain difficulties be addressed within an EU pharmaceutical technique predicted for being introduced by the end